|
|
|
| home > white papers > R&D to Product: How to Reduce Costly Scale-Up Problems - Natoli Engineering Company, Inc. |
|
|
 WHITE PAPERS |
|
Natoli Engineering Company, Inc.
|
|
R&D to Product: How to Reduce Costly Scale-Up Problems
|
|
When scaling a new drug formulation from the development side of R&D into manufacturing, there is often a reality check with respect to process scaleup and performance of the formulation at production levels. Problems with capping/lamination and sticking/ picking are often first realized when a formulation is introduced to a level of compression required to supply market demand.
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Axol Bioscience introduces multi-electrode array screening services for human iPSC-derived cells
• Expansion of Axol Bioscience’s service offering for pre-clinical drug discovery
• New services combine the Company’s iPSC-derived human cells and electrophysiological expertise with Axion Biosystems’ Maestro Pro MEA platform
More info >> |
|
 |
White Papers |
 |
|
The Importance of ADCC in Assessing Clinically Relevant Differences
Sartorius Stedim BioOutsource Ltd
Biosimilars have caused a revolution in the development of biologic drugs. The model for biosimilars is a combination of speed to market and low cost; these are fundamental to any biosimilar development project. The biosimilars pathway to approval is not always without difficulty, biosimilars are still relatively new, and as each new applicant is reviewed we are learning more and more about these molecules.
More info >> |
|
 |
Industry Events |
 |
Bio Integrates 2021
20 May 2021, VIRTUAL CONFERENCE
Following the continued success of last year’s inaugural digital event,
Life Science Integrates is delighted to announce the 3rd Bio Integrates
conference. Addressing the needs of innovative companies developing the
therapies of tomorrow, this one-day conference provides a unique forum
to discuss the major challenges impacting the sector.
More info >> |
|
|
|
